PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer

A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes

(2012) Benjamin Haibe-Kains et al.   JNCI-Journal of the National Cancer Institute

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

DNA methylation profiling reveals a predominant immune component in breast cancers

(2011) Sarah Dedeurwaerder et al.   EMBO Molecular Medicine

Practical implications of gene-expression-based assays for breast oncologists

(2011) Aleix Prat et al.   Nature Reviews Clinical Oncology

Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer

(2010) W. Fraser Symmans et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical implementation of the intrinsic subtypes of breast cancer

(2010) Charles M Perou et al.   LANCET ONCOLOGY

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER Status

(2010) Qiyuan Li et al.   PLoS One

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Genes that mediate breast cancer metastasis to the brain

(2009) Paula D. Bos et al.   NATURE

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

(2008) Yi Zhang et al.   BREAST CANCER RESEARCH AND TREATMENT

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH